Evaluation of Antibiotic Prescribing Pattern Using WHO Access, Watch and Reserve Classification in Kinshasa, Democratic Republic of Congo
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Environment
2.2. Administrative Documents
2.3. Methods Used
2.4. Data Collection and Analysis
3. Results
4. Discussion
4.1. Single Antibiotic Prescription
4.2. Prescription of Two Antibiotics
4.3. Prescription of Three Antibiotics
4.4. Prescription to Four Antibiotics
4.5. Summary Study of 301 Medical Prescriptions
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- OMS. Plan D’action Mondial Pour Combattre la Résistance aux Antimicrobiens. 2016. Available online: https://apps.who.int/iris/bitstream/handle/10665/249548/9789242509762-fre.pdf (accessed on 25 May 2022).
- OMS. Guide Pour Établir la Surveillance en Laboratoire de la Résistance aux Antimicrobiens. 2013. Available online: https://www.afro.who.int/sites/default/files/2017-06/guide-for-establishing-lab-based-surveillance-for-amr-fr.pdf (accessed on 12 May 2022).
- Akinde, O.S.; Taiwo, M.O. Emerging antibiotic resistance in Africa, threat to healthcare delivery. MOJ Biol. Med. 2017, 1, 114–115. [Google Scholar]
- Haut conseil de la Santé Publique. Recommandations Relatives aux Mesures pour Prévenir L’émergence des Entérobactéries BLSE et Lutter Contre Dissemination. 2008. Available online: https://www.preventioninfection.fr/document/recommandations-relatives-aux-mesures-a-mettre-en-oeuvre-pour-prevenir-lemergence-des-enterobacteries-blse-et-lutter-contre-leur-dissemination/ (accessed on 28 May 2022).
- Chouchani, C.; Marra Chi, R.; El Salabi, A. Evolution of beta-lactams resistance in Gram–negative bacteria in Tunisia. Crit. Rev. Microbiol. 2011, 37, 167–177. [Google Scholar] [CrossRef] [PubMed]
- Ghenghesh, K.S.; Rahouma, A.; Tawil, K.; Zorgani, A.; Franca, E. Antimicrobial resitance in Libya: 1970–2011. Libyan J. Med. 2013, 8, 1–8. [Google Scholar]
- Thriemer, K.; Katuala, Y.; Batoko, B.; Alworonga, J.-P.; Devlieger, H.; Van Geet, C.; Ngbonda, D.; Jacobs, J. Antibiotic Prescribing in DR Congo: A Knowledge, Attitude and Practice Survey among Medical Doctors and Students. PLoS ONE 2013, 8, e55495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Phoba, M.F.; Lunguya, O.; Mayimon, D.V.; Lewo di Mputu, P.; Bertrand, S.; Vanhoof, R.; Verhaegen, J.; Van Geet, C.; Muyembe, J.J.; Jacobs, J. Multidrug-resistant Salmonella enterica, Democratic Republic of oothe Congo. Emerg. Infect. Dis. 2012, 18, 1692–1694. [Google Scholar] [CrossRef] [Green Version]
- De Boeck, H.; Lunguya, O.; Muyembe, J.-J.; Glupczynski, Y.; Jacobs, J. Presence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in waste waters, Kinshasa, the Democratic Republic of the Congo. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 3085–3088. [Google Scholar] [CrossRef]
- Iyamba, J.-M.L.; Wambale, J.M.; Takaisi-Kikuni, N.Z.B. Antimicrobial susceptibility patterns of enterobacteriaceae isolated from HIV-infected patients in Kinshasa. Pan Afr. Med. J. 2014, 17, 179. [Google Scholar] [CrossRef]
- Iyamba, J.-M.L.; Wambale, J.M.; Lukukula, C.M.; Takaisi-Kikuni, N.Z.B. High prevalence of methicillin resistant staphylococci strains isolated from surgical site infections in Kinshasa. Pan Afr. Med. J. 2014, 18, 322. [Google Scholar] [CrossRef]
- Ministère de la Santé Public RDC. Plan National de Développement Sanitaire 2016–2020. 2016. Available online: https://www.childrenandaids.org/sites/default/files/2017-11/pnds_2016-2020.pdf (accessed on 25 May 2022).
- OMS; FAO; OIE. Antimicrobial Resistance: A manual for Developing National Action Plans. 2016. Available online: https://apps.who.int/iris/bitstream/handle/10665/204470/9789241549530_eng.pdf?sequence=1&isAllowed=y (accessed on 25 May 2022).
- World Health Organization (WHO). The World Medicine Situation; WHO Press, World Health Organization: Geneva, Switzerland, 2004; Available online: https://apps.who.int/iris/bitstream/handle/10665/68735/WHO_EDM_PAR_2004.5.pdf?sequence=1&isAllowed=y (accessed on 26 May 2022).
- World Health Organization (WHO). Perspectives Politiques de l’OMS sur les Médicaments; World Health Organization: Geneva, Switzerland, 2002. [Google Scholar]
- Mbuyi, J.; Ngalula, H.; Okond’ahoka, J. A Propos de L’observance des règles de Prescriptions Médicales à Kinshasa; Revue du C.R.I.D.U.P.N.: Kinshasa, Democratic Republic of Congo, 2017; pp. 315–326. [Google Scholar]
- Muya, B. Évaluation de la qualité de la prescription médicale dans la ville de Mbuji-Mayi/Kasaï-Oriental en République Démocratique du Congo. Rev. Médicale Grands Lacs 2015, 2, 361–368. [Google Scholar]
- Tsakala, T.M.; Tona, G.L.; Mesia, K.; Mboma, J.C.; Vangu, J.M.; Voso, S.M.; Kanja, G.L.; Kodondi, K.K.; Mabela, M.; Walo, R.; et al. Evaluation of prescriptions for inpatient treatment of malaria and gastroenteritis: Bondeko and St Joseph hospitals in Kinshasa. Santé 2005, 15, 119–124. [Google Scholar]
- Katengele, K.; Kiniati, F.; Isalomboto, N.; Mana, D.K. The Potential Impact of Self-medication and Drug Misuse Practice Among Youth Population in Kinshasa, Democratic Republic of Congo. Am. J. Biomed. Life Sci. 2021, 9, 69. [Google Scholar] [CrossRef]
- In the Face of Slow Progess Who Offers a New Tool and Sets a Target to Accelerate Action against Antimicribial. Available online: https://www.WHO.int/fr/news/item/18-06-2019 (accessed on 1 June 2022).
- Nguyen, N.V.; Do, N.T.T.; Nguyen, C.T.K.; Tran, T.K.; Ho, P.D.; Nguyen, H.H.; Vu, H.T.L.; Wertheim, H.F.L.; Van Doorn, H.R.; Lewycka, S. Community-level consumption of antibiotics according to the AWaRe (Access, Watch, Reserve) classification in rural Vietnam. JAC-Antimicrob. Resist. 2020, 2, 1098. [Google Scholar] [CrossRef] [PubMed]
- Zhussupova, G.; Utepova, D.; Orazova, G.; Zhaldybayeva, S.; Skvirskaya, G.; Tossekbayev, K. Evaluation of Antibiotic Use in Kazakhstan for the Period 2017–2019 Based on WHO Access, Watch and Reserve Classification (AWaRe 2019). Antibiotics 2021, 10, 58. [Google Scholar] [CrossRef] [PubMed]
- Islam, A.; Akhtar, Z.; Hassan, Z.; Chowdhury, S.; Rashid, M.; Aleem, M.A.; Ghosh, P.K.; Mah-E-Muneer, S.; Parveen, S.; Ahmmed, K.; et al. Pattern of Antibiotic Dispensing at Pharmacies According to the WHO Access, Watch, Reserve (AWaRe) Classification in Bangladesh. Antibiotics 2022, 11, 247. [Google Scholar] [CrossRef] [PubMed]
- Pauwels, I.; Versporten, A.; Drapier, N.; Vlieghe, E.; Goossens, H. Hospital antibiotic prescribing in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): Results from a worldwide point prevalence survey in 69 countries. J. Antimicrob. Chemother 2021, 76, 1614–1624. [Google Scholar] [CrossRef]
- Hsia, Y.; Lee, B.R.; Versporten, A.; Yang, Y.; Bielicki, J.; Jackson, C.; Newland, J.; Goossens, H.; Magrini, N.; Sharland, M.; et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): An analysis of paediatric survey data from 56 countries. Lancet Glob. Health 2019, 7, e861–e871. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- WHO Model List of Essential Medicines (20th List). 2017. Available online: https://www.who.int/medicines/news/2017/20th_essential_med-list/en/ (accessed on 28 May 2022).
- Kacou-Ndouba, A.; Revathi, G.; Mwathi, P.; Seck, A.; Diop, A.; Kabedi-Bajani, M.J.; Mwiti, W.; Anguibi-Pokou, M.J.; Morrissey, I.; Torumkuney, D. Results from the Survey of Antibiotic Resistance (SOAR) 2011–14 in the Democratic Republic of Congo, Ivory Coast, Republic of Senegal and Kenya. J. Antimicrob. Chemother. 2016, 71 (Suppl. S1), i21–i31. [Google Scholar] [CrossRef] [Green Version]
- WHO Access, Watch, Reserve (AWaRe) Classification of Antibiotics for Evaluation and Monitoring of Use. 2021. Available online: https://www.who.int/publications/i/item/2021-aware-classification (accessed on 28 May 2022).
- Slimings, C.; Riley, T.V. Antibiotics and hospital-acquired Clostridium difficile infection: Update of systematic review and meta-analysis. J. Antimicrob. Chemother. 2014, 69, 881–891. [Google Scholar] [CrossRef]
- Wilcox, M.H.; Mooney, L.; Bendall, R.; Settle, C.D.; Fawley, W.N. A case–control study of community-associated Clostridiumdifficile infection. J. Antimicrob. Chemother. 2008, 62, 388–396. [Google Scholar] [CrossRef] [Green Version]
- Bergman, M.; Huikko, S.; Huovinen, P.; Paakkari, P.; Seppälä, H. Macrolide and Azithromycin Use Are Linked to Increased Macrolide Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2006, 50, 3646–3650. [Google Scholar] [CrossRef] [Green Version]
- Song, J.-H.; Jung, S.-I.; Ko, K.S.; Kim, N.Y.; Son, J.S.; Chang, H.-H.; Ki, H.K.; Oh, W.S.; Suh, J.Y.; Peck, K.R.; et al. High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study). Antimicrob. Agents Chemother. 2004, 48, 2101–2107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
No. | Antibiotics Generic Names | n = 164/(%) | Category (%) |
---|---|---|---|
1 | Amoxicillin | 22 (13.4) | Access 54:32.9% |
2 | Amoxicillin/clavulanic-acid | 20 (12.2) | |
3 | Flucloxacillin | 5 (3,0) | |
4 | Cefadroxil | 2 (1.2) | |
5 | Metronidazole | 2 (1.2) | |
6 | Doxycycline | 1 (0.6) | |
7 | Penicillin | 1 (0.6) | |
8 | Cefalexin | 1 (0.6) | |
9 | Ceftriaxone | 51 (31.1) | Watch 110:67.1% |
10 | Azithromycin | 17 (10.4) | |
11 | Ciprofloxacin | 12 (7.3) | |
12 | Cefixime | 10 (6.1) | |
13 | Lincomycin | 6 (3.7) | |
14 | Cefotaxime | 4 (2.4) | |
15 | Cefpodoxime | 3 (1.8) | |
16 | Erythromycin | 3 (1.8) | |
17 | Ofloxacin | 2 (1.2) | |
18 | Levofloxacin | 1 (0.6) | |
19 | Streptomycin | 1 (0.6) | |
TOTAL | 164 (100) | 164:100% |
No. | Antibiotics Generic Names | n = 117/(%) | Category (%) |
---|---|---|---|
1 | Amoxicillin + Gentamicin | 6 (5.13) | Access 21 (18) |
2 | Amoxicillin + Furazidin | 1 (0.85) | |
3 | Amoxicillin + Amikacin | 1 (0.85) | |
4 | Amoxicillin/clavulanic-acid +Metronidazole | 3 (2.56) | |
5 | Amoxicillin/clavulanic-acid +Furazidin | 2 (1.71) | |
6 | Amoxicillin/clavulanic-acid + Ornidazole | 1 (0.85) | |
7 | Metronidazole + Furazidin | 2 (1.71) | |
8 | Metronidazole + Doxicycline | 1 (0.85) | |
9 | Metronidazole + Cefadroxil | 1 (0.85) | |
10 | Chloramphénicol + Gentamicin | 1 (0.85) | |
11 | Flucloxacillin + Metronidazole | 1 (0.85) | |
12 | Penicillin + Doxycycline | 1 (0.85) | |
13 | Ceftriaxone + Gentamicin | 15 (12.82) | Watch 62 (53) |
14 | Ceftriaxone + Amoxicillin | 11 (9.40) | |
15 | Ceftriaxone + Metronidazole | 8 (6.84) | |
16 | Ceftriaxone + Lincomycin | 3 (2.56) | |
17 | Ceftriaxone + Cefixime | 1 (0.85) | |
18 | Ceftriaxone + Doxycycline | 1 (0.85) | |
19 | Ceftriaxone + Ornidazole | 1 (0.85) | |
20 | Ceftriaxone + Chloramphenicol | 1 (0.85) | |
21 | Ceftriaxone + Clindamycin | 1 (0.85) | |
22 | Ceftriaxone + Ciprofloxacin | 1 (0.85) | |
23 | Lincomycin + Amoxicillin | 2 (1.71) | |
24 | Lincomycin + Gentamicin | 1 (0.85) | |
25 | Lincomycin + Kanamycin | 1 (0.85) | |
26 | Lincomycin + Cefuroxime | 1 (0.85) | |
27 | Lincomycin + Ofloxacin | 1 (0.85) | |
28 | Azithromycin + Amoxicillin | 2 (1.71) | |
29 | Azithromycin + Doxycycline | 2 (1.71) | |
30 | Ciprofloxacin + Amoxicillin | 1 (0.85) | |
31 | Ciprofloxacin + Cefadroxil | 1 (0.85) | |
32 | Ciprofloxacin + Furazidin | 1 (0.85) | |
33 | Cefotaxime + Chloramphenicol | 1 (0.85) | |
34 | Cefotaxime + Amoxicillin | 2 (1.71) | |
35 | Cefixime + Amoxicillin | 1 (0.85) | |
36 | Kanamycin + Ornidazole | 1 (0.85) | |
37 | Erythromycin + Penicillin | 1 (0.85) | |
38 | Norfloxacin/Metronidazole | 8 (6.84) | not recommended 34 (29) |
39 | Ofloxacin/Ornidazole | 8 (6.84) | |
40 | Ciprofloxacin/Metronidazole | 7 (5.98) | |
41 | Ceftriaxone/Sulbactam | 6 (5.13) | |
42 | Ceftriaxone/Tazobactam | 2 (1.71) | |
43 | Ciprofloxacine/Ornidazole | 2 (1.71) | |
44 | Cefixime/Ornidazole | 1 (0.85) | |
TOTAL | 117 (100) | 117 (100) |
No. | Antibiotics Generic Names | n = 15/(%) | Category (%) |
---|---|---|---|
1 | Penicillin + Chloramphenicol + Doxycycline | 1 (6.67) | Access 1 (6.6) |
2 | Ceftriaxone + Gentamicin +Chloramphenicol | 1 (6.67) | Watch 7 (46.7) |
3 | Ceftriaxone + Penicillin + Amoxicillin | 1 (6.67) | |
4 | Ceftriaxone + Gentamicin + Furazidin | 1 (6.67) | |
5 | Cefotaxime + Metronidazole + Doxycycline | 1 (6.67) | |
6 | Ceftriaxone + Lincomycin + Gentamicin | 1 (6.67) | |
7 | Lincomycin + Ceftriaxone + Sulbactam | 1 (6.67) | |
8 | Cefotaxime + Azythromycin + Oxacillin | 1 (6.67) | |
9 | Ceftriaxone + Sulbactam + Ornidazole | 1 (6.67) | not recommended 7 (46.7) |
10 | Ceftriaxone + Sulbactam + Amoxicillin | 1 (6.67) | |
11 | Ceftriaxone + Sulbactam + Metronidazole | 1 (6.67) | |
12 | Ceftriaxone + Sulbactam + Cefixime | 1 (6.67) | |
13 | Ceftriaxone + Sulbactam + Lévofloxacine | 1 (6.67) | |
14 | Ciprofloxacin/Metronidazole + Cefotaxime | 1 (6.67) | |
15 | Ofloxacin/Ornidazole (A) + Azythromycin | 1 (6.67) | |
TOTAL | 15 (100) | 15 (100) |
No. | Antibiotics Generic Names | n = 5/(%) | Category n (%) |
---|---|---|---|
1 | Ceftriaxone/Metronidazole + Ofloxacin + Ornidazole | 1 (20) | not recommended 5 (100) |
2 | Ceftriaxone/Sulbactam + Norfloxacin + Metronidazole | 1 (20) | |
3 | Norfloxacin/Metronidazole + Erythromycin + Ornidazole | 1 (20) | |
4 | Ceftriaxone/Sulbactam + Lincomycin + Metronidazole | 1 (20) | |
5 | Ceftriaxone/Cefixime + Norfloxacin/Metronidazole | 1 (20) | |
TOTAL | 5 (100) | 5 (100) |
No. | Antibiotics Generic Names | n = 463(%) | Category (%) |
---|---|---|---|
1 | Amoxicillin | 51 (11.01) | Access 169 (36.5) |
2 | Metronidazole | 22 (4.75) | |
3 | Gentamicin | 26 (5.61) | |
4 | Amoxicillin/acide clavulanic-acid | 26 (5.61) | |
5 | Ornidazole | 5 (1.08) | |
6 | Doxycycline | 8 (1.73) | |
7 | Furazidin | 7 (1.51) | |
8 | Flucloxacillin | 6 (1.30) | |
9 | Chloramphenicol | 5 (1.08) | |
10 | Penicillin | 5 (1.08) | |
11 | Cefadroxil | 4 (0.86) | |
16 | Cefalexime | 1 (0.21) | |
17 | Clindamycin | 1 (0.21) | |
18 | Oxacilline | 1 (0.21) | |
19 | Amikacin | 1 (0.21) | |
20 | Ceftriaxone | 101 (21.38) | Watch 200 (43.20) |
21 | Ciprofloxacin | 17 (3.67) | |
22 | Azithromycin | 23 (4.97) | |
23 | Lincomycin | 18 (3.89) | |
24 | Cefixime | 14 (3.02) | |
25 | Ofloxacin | 3 (0.65) | |
26 | Cefotaxime | 10 (2.15) | |
27 | Erythromycin | 5 (1.08) | |
28 | Cefpodoxime | 3 (0.65) | |
29 | Kanamycin | 2 (0.43) | |
30 | Levofloxacin | 2 (0.43) | |
31 | Cefuroxime | 1 (0.21) | |
32 | Streptomycin | 1 (0.21) | |
33 | Ceftriaxone/Sulbactam | 28 (5.61) | 94 (20.30) Not recommended |
34 | Norfloxacin/Metronidazole | 20 (4.32) | |
35 | Ofloxacin/Ornidazole | 18 (3.89) | |
36 | Ciprofloxacin/Metronidazole | 16 (3.45) | |
37 | Ceftriaxone/Tazobactam | 4 (0.86) | |
38 | Ciprofloxacin/Ornidazole | 4 (0.86) | |
39 | Cefixime/Ornidazole | 2 (0.43) | |
40 | Norfloxacin/Metronidazole | 2 (0.43) | |
TOTAL | 463 (100) |
No. | WHO ATC Group | Antibiotics Classes | n = 463(%) | Category (%) |
---|---|---|---|---|
1 | J01CF05 | Penicillins | 63 (13.61) | Access 169 (36.5) |
2 | J01XD01 | Imidazoles | 27 (5.83) | |
3 | J01GB03 | Aminoglycosides | 27 (5.83) | |
4 | J01CR02 | Beta-lactamase inhibitor | 26 (5.61) | |
5 | J01AA02 | Tetracyclines | 8 (1.73) | |
6 | J01XE01 | Nitrofuran-derivatives | 7 (1.51) | |
7 | J01BA01 | Amphenicols | 5 (1.08) | |
8 | J01DB05 | First-generation cephalosporins | 5 (1.08) | |
9 | J01FF01 | Lincosamides | 1 (0.21)) | |
10 | J01DD04 | Third-generation cephalosporins | 128 (27.65) | Watch 200 (43.2) |
11 | J01FA10 | Macrolides | 28 (6.05) | |
12 | J01MA12 | Fluoroquinolones | 22 (4.75) | |
13 | J01FF02 | Lincosamides | 18 (3.89) | |
14 | A07AA08 | Aminoglycosides | 3 (0.65) | |
15 | J01DC02 | Second-generation cephalosporins | 1 (0.21) | |
16 | Third-generation-cephalosporins/Beta-lactamase-inhibitors | 30 (6.48) | Not-recommended 94 (20.3) | |
17 | Fluoroquinolones/Imidazoles | 60 (12.96) | ||
18 | Third-generation-cephalosporins/Imidazoles | 4 (0.86) | ||
TOTAL | 463 (100) |
Antibiotics | Africa | America | Europe | Southwest Asia |
---|---|---|---|---|
Amoxicillin | 6.4% | 3.3% | 3.6% | 2.5% |
Amoxicillin + Clav. Acid | 4.9% | 2.4% | 9.1% | 8.9% |
Azithromycin | 2.1% | 3.2%% | 3.4% | 1.9% |
Ceftriaxone | 12.0% | 9.8% | 10.1% | 15.4% |
Ciprofloxacin | 3.8% | 2.1% | 2.9% | 2.5% |
Gentamicin | 10.0% | 1.6% | 4.3% | 0.0% |
Metronidazole | 5.5% | 4.7% | 3.7% | 5.0% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kakumba, J.M.; Kindenge, J.M.; Kapepula, P.M.; Iyamba, J.-M.L.; Mashi, M.L.; Mulwahali, J.W.; Kialengila, D.M. Evaluation of Antibiotic Prescribing Pattern Using WHO Access, Watch and Reserve Classification in Kinshasa, Democratic Republic of Congo. Antibiotics 2023, 12, 1239. https://doi.org/10.3390/antibiotics12081239
Kakumba JM, Kindenge JM, Kapepula PM, Iyamba J-ML, Mashi ML, Mulwahali JW, Kialengila DM. Evaluation of Antibiotic Prescribing Pattern Using WHO Access, Watch and Reserve Classification in Kinshasa, Democratic Republic of Congo. Antibiotics. 2023; 12(8):1239. https://doi.org/10.3390/antibiotics12081239
Chicago/Turabian StyleKakumba, Jocelyn Mankulu, Jérémie Mbinze Kindenge, Paulin Mutwale Kapepula, Jean-Marie Liesse Iyamba, Murielle Longokolo Mashi, Jose Wambale Mulwahali, and Didi Mana Kialengila. 2023. "Evaluation of Antibiotic Prescribing Pattern Using WHO Access, Watch and Reserve Classification in Kinshasa, Democratic Republic of Congo" Antibiotics 12, no. 8: 1239. https://doi.org/10.3390/antibiotics12081239
APA StyleKakumba, J. M., Kindenge, J. M., Kapepula, P. M., Iyamba, J. -M. L., Mashi, M. L., Mulwahali, J. W., & Kialengila, D. M. (2023). Evaluation of Antibiotic Prescribing Pattern Using WHO Access, Watch and Reserve Classification in Kinshasa, Democratic Republic of Congo. Antibiotics, 12(8), 1239. https://doi.org/10.3390/antibiotics12081239